tiprankstipranks
Trending News
More News >
Aura Biosciences Inc (AURA)
NASDAQ:AURA
US Market

Aura Biosciences Inc (AURA) AI Stock Analysis

Compare
216 Followers

Top Page

AU

Aura Biosciences Inc

(NASDAQ:AURA)

Rating:43Neutral
Price Target:
Aura Biosciences' overall stock score reflects its early-stage biotech profile, characterized by no revenue, increasing losses, and negative cash flows. While the company maintains a solid balance sheet, its stock faces bearish technical indicators and speculative valuation. The recent board appointment is a positive development, but the company's financial health and market trends remain the primary concerns.
Positive Factors
Clinical Trials
Bel-sar has demonstrated tumor control in up to 80% of treated patients and 90% vision preservation in choroidal melanoma.
Financial Performance
The company has $151 million in cash and cash equivalents, providing financial runway into the second half of 2026.
Innovation
Aura filed a patent application for a new bladder cancer formulation to increase ease of administration, suggesting innovation and potential for improved treatment options.
Negative Factors
Market Adoption
The market model has been adjusted to reflect a slower adoption of the immune-ablative approach for intermediate-risk patients, as it deviates more from current practice.
Market Projections
Overall peak sales for bel-sar in bladder are now estimated at $800 million, down from a previous estimate of $1.1 billion.
Regulatory Concerns
Concerns about the single arm design of the ENVISION trial, which the FDA views as insufficient to assess duration of response.

Aura Biosciences Inc (AURA) vs. SPDR S&P 500 ETF (SPY)

Aura Biosciences Inc Business Overview & Revenue Model

Company DescriptionAura Biosciences Inc (AURA) is a biotechnology company focused on developing novel therapies for the treatment of various cancers. The company's core product candidates are designed to selectively target and destroy cancer cells while minimizing damage to surrounding healthy tissues. Aura Biosciences is particularly known for its work in ocular oncology, including the development of proprietary virus-like drug conjugates that target ocular and other rare cancers.
How the Company Makes MoneyAura Biosciences generates revenue primarily through the development and potential commercialization of its proprietary cancer therapies. The company aims to make money by obtaining regulatory approval for its drug candidates and subsequently commercializing them either independently or through strategic partnerships with larger pharmaceutical companies. Revenue streams may include upfront payments, milestone payments, and royalties from licensing agreements, as well as direct sales of approved therapies. Significant partnerships with established pharmaceutical companies can also contribute to its earnings by providing financial support and market access for its products.

Aura Biosciences Inc Financial Statement Overview

Summary
Aura Biosciences Inc. is an early-stage biotech firm with no revenue and increasing net losses. Despite strong equity positions and manageable debt levels, the company's continued negative cash flows necessitate strategic funding and revenue generation strategies to sustain operations.
Income Statement
30
Negative
Aura Biosciences Inc. has consistently reported zero revenue over the years, indicating a pre-revenue or early-stage biotech company. Net losses have increased from -$24.2M in 2019 to -$86.9M in 2024, reflecting higher operational expenses likely due to R&D and other growth activities. Although this is typical for biotech firms in early stages, the absence of revenue presents a significant financial risk.
Balance Sheet
55
Neutral
The company's balance sheet improved in terms of equity, turning from negative in 2019 to positive in recent years, with a stockholders' equity of $151.97M in 2024. The debt-to-equity ratio is low, indicating manageable debt levels relative to equity. However, the absence of revenue to cover liabilities presents a risk if financing becomes constrained.
Cash Flow
45
Neutral
Operating cash flow remains negative, with a significant increase in cash burn over the years, reaching -$79.8M in 2024. Despite negative free cash flow, the company has maintained significant cash reserves, likely due to financing activities, evidenced by substantial cash and equivalents of $151.09M. This provides a buffer but raises sustainability concerns if cash outflows persist without revenue.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit-313.00K0.00-1.29M-1.18M-835.00K-831.00K
EBITDA-72.88M-85.58M-83.70M-59.12M-34.42M-21.38M
Net Income-94.70M-86.92M-76.41M-57.23M-34.42M-22.21M
Balance Sheet
Total Assets155.40M182.50M255.07M223.94M160.03M22.10M
Cash, Cash Equivalents and Short-Term Investments127.99M151.09M226.15M188.81M149.06M17.39M
Total Debt18.44M18.77M19.56M20.86M975.00K15.00K
Total Liabilities27.43M30.53M29.23M28.35M7.71M130.82M
Stockholders Equity127.97M151.97M225.85M195.58M152.31M-108.71M
Cash Flow
Free Cash Flow-80.06M-81.06M-64.56M-55.70M-34.53M-25.09M
Operating Cash Flow-78.71M-79.81M-63.85M-54.60M-32.41M-24.32M
Investing Cash Flow89.24M68.82M-113.96M-67.87M-2.13M-771.00K
Financing Cash Flow1.44M1.59M97.29M95.63M166.26M10.04M

Aura Biosciences Inc Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6.55
Price Trends
50DMA
5.87
Positive
100DMA
6.49
Positive
200DMA
7.79
Negative
Market Momentum
MACD
0.11
Positive
RSI
57.04
Neutral
STOCH
27.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AURA, the sentiment is Positive. The current price of 6.55 is above the 20-day moving average (MA) of 6.28, above the 50-day MA of 5.87, and below the 200-day MA of 7.79, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 57.04 is Neutral, neither overbought nor oversold. The STOCH value of 27.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AURA.

Aura Biosciences Inc Risk Analysis

Aura Biosciences Inc disclosed 71 risk factors in its most recent earnings report. Aura Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Aura Biosciences Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
$497.87M-62.43%-0.90%-89.51%
54
Neutral
$651.21M-159.34%-48.97%69.32%
52
Neutral
$284.79M69.052.88%61.09%
51
Neutral
$443.24M-79.51%-100.00%10.73%
46
Neutral
$286.69M-41.59%0.42%
46
Neutral
C$186.44M-4.26-8.56%3.08%13.68%-1.94%
43
Neutral
$374.51M-56.24%9.22%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AURA
Aura Biosciences Inc
6.55
-0.58
-8.13%
ATYR
aTyr Pharma
5.31
3.78
247.06%
TSHA
Taysha Gene Therapies
2.37
0.33
16.18%
OLMA
Olema Pharmaceuticals
4.69
-6.37
-57.59%
ATAI
ATAI Life Sciences
2.11
0.81
62.31%
GLUE
Monte Rosa Therapeutics
4.74
1.05
28.46%

Aura Biosciences Inc Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Aura Biosciences Expands Board with New Director Appointment
Positive
Apr 2, 2025

On March 31, 2025, Aura Biosciences expanded its Board of Directors by appointing Teresa Marie Bitetti as a Class II director. Bitetti, who is the President of the Global Oncology Business Unit at Takeda, brings extensive operational and commercial experience to the board. Her appointment is expected to strengthen Aura’s strategic direction as it advances its clinical pipeline in ocular and urologic oncology. Bitetti’s industry expertise is anticipated to support Aura’s mission to grow as an innovative global oncology company.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025